Janssen Research & Development
Part of Johnson & Johnson
CompanyUnited StatesFounded 2001
Janssen Research & Development develops 21 assets, the furthest approved (amivantamab in non-small cell lung cancer). Mostly small molecule and antibody acting on EGFR, MET and SLC5A2; based in the United States, founded in 2001.
- 21
- Assets
- Furthest stage
- Approved
- 727
- Trials
- 188
- Signals
Pipeline
21Bispecific antibody targeting EGFR and MET, blocking signaling and promoting immune-mediated tumor cell killing.
Approved, Antibody, EGFR, MET, non-small cell lung cancer, locally advanced or metastatic non small cell lung cancer
Fixed-dose combination of DPP-4 inhibitor teneligliptin and SGLT2 inhibitor canagliflozin to improve glycemic control
Approved, Small molecule, SLC5A2, type 2 diabetes, diabetic kidney disease
Anti-CD38 monoclonal antibody inducing targeted immune-mediated lysis of CD38-expressing cells.
Approved, Antibody, CD38, multiple myeloma, newly diagnosed multiple myeloma
18 more assets
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms11
- Trials826
- Signals20
- Integrity notices4
- Similar companies6
Papers
Genomic analyses implicate hormonal and metabolic dysregulation in polycystic ovary syndrome
Nature genetics, Apr 24, 2026
Communications medicine, Mar 14, 2026
Research Square, Feb 18, 2026
medRxiv : the preprint server for health sciences, Nov 19, 2025
Nature aging, Aug 6, 2025
The journal of prevention of Alzheimer's disease, Jul 24, 2025
JACC. CardioOncology, Feb 19, 2025
Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection
Nature medicine, Jan 31, 2025
Brain : a journal of neurology, Jan 29, 2025
American journal of hypertension, Aug 9, 2024
GeroScience, Jul 5, 2024
Genomic and proteomic evidence for hormonal and metabolic foundations of polycystic ovary syndrome
medRxiv, Apr 19, 2024
NPJ digital medicine, Dec 19, 2023
Diabetes, obesity & metabolism, Dec 23, 2022
Alzheimer's & dementia (Amsterdam, Netherlands), Oct 4, 2022
Hip Fracture Risk After Treatment with Tramadol or Codeine: An Observational Study
Drug safety, Jul 10, 2022
Contemporary clinical trials, Mar 12, 2022
Translational psychiatry, Jul 24, 2021
Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition, Jun 19, 2021
PloS one, Nov 6, 2020